Cost study of eye injections for new macular degeneration
Part of Eyes & vision clinical trials.
This study evaluates the cost-effectiveness of three anti-VEGF eye injection treatments (bevacizumab, ranibizumab, or aflibercept) for patients with newly diagnosed age-related macular degeneration affecting the center of vision. The research aims to understand which treatment option provides the best medical and financial value in France.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neovascular age-related macular degeneration (wet AMD) that has not been treated before
- The wet AMD affects the center of your vision (foveal area) and may affect one or both eyes
- You have not had anti-VEGF eye injections or AMD surgery in the past 2 months in the eye being studied
- You are not pregnant or breastfeeding, and if you could become pregnant, you use effective birth control
- You are enrolled in French social security (health insurance)
- You do not have severe eye inflammation, active eye infection, or uncontrolled high eye pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial compares two standard anti-VEGF injections (aflibercept and bevacizumab) for people with diabetic macular edema who have not recently had this treatment. The goal is to see which drug works better over three monthly doses to improve vision and reduce retinal swelling.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This study looks at how repeated eye injections of a drug called bevacizumab affect chemicals in your blood that relate to heart health and inflammation. Researchers want to understand if these eye injections might impact your cardiovascular risk.
Hear when a new Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.